

Resource Summary Report

Generated by [RRID](#) on Sep 2, 2026

NB4

RRID:CVCL_0005

Type: Cell Line

Proper Citation

RRID:CVCL_0005

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0005

Proper Citation: RRID:CVCL_0005

Description: Cell line NB4 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Acute promyelocytic leukemia with PML-RARA

Defining Citation: [PMID:1453773](#), [PMID:1995093](#), [PMID:7630193](#), [PMID:9737686](#), [PMID:11704857](#), [PMID:12353268](#), [PMID:14504097](#), [PMID:15843827](#), [PMID:16408098](#), [PMID:16957166](#), [PMID:22460905](#), [PMID:23325432](#), [PMID:23955599](#), [PMID:25877200](#), [PMID:25894527](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:35839778](#), [PMID:36982453](#)

Comments: Population: Caucasian., Part of: LL-100 blood cancer cell line panel., Part of: Human Protein Atlas, Cell Atlas panel., Part of: ENCODE project common cell types; tier 3., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Patented cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NB4

Synonyms: NB-4, NB.4

Cross References: BTO:BTO_0002136, CLO:CLO_0007947, EFO:EFO_0002798, MCCL:MCC:0000350, CLDB:cl3643, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-

7722, BioGRID_ORCS_Cell_line:212, BioSample:SAMN03470835, BioSample:SAMN10988571, cancercelllines:CVCL_0005, Cell_Model_Passport:SIDM00428, ChEMBL-Cells:CHEMBL3308423, ChEMBL-Targets:CHEMBL614188, CLS:300299, Cosmic:787463, Cosmic:850391, Cosmic:922661, Cosmic:924050, Cosmic:975285, Cosmic:981582, Cosmic:996313, Cosmic:1012107, Cosmic:1037664, Cosmic:1070692, Cosmic:1078721, Cosmic:1089522, Cosmic:1127257, Cosmic:1181601, Cosmic:1523826, Cosmic:1524838, Cosmic:1601063, Cosmic:1604862, Cosmic:1779130, Cosmic:2036677, Cosmic:2089653, Cosmic:2131548, Cosmic:2306227, Cosmic:2579202, Cosmic-CLP:1323913, DepMap:ACH-000294, DSMZ:ACC-207, DSMZCellDive:ACC-207, EGA:EGAS00001000978, ENCODE:ENCBS032SIL, ENCODE:ENCBS259AAA, ENCODE:ENCBS390ENC, GDSC:1323913, GEO:GSM236798, GEO:GSM236834, GEO:GSM472929, GEO:GSM510512, GEO:GSM510513, GEO:GSM749716, GEO:GSM887349, GEO:GSM888426, GEO:GSM945252, GEO:GSM945275, GEO:GSM1022643, GEO:GSM1374696, GEO:GSM1374697, GEO:GSM1446740, GEO:GSM1670151, GEO:GSM7701453, GEO:GSM7701458, IARC_TP53:21530, IARC_TP53:21705, LiGeA:CCL_910, LINCS_LDP:LCL-1084, Lonza:749, NCBI_Iran:C515, PharmacDB:NB4_990_2019, PRIDE:PXD000589, PRIDE:PXD001610, PRIDE:PXD030304, Progenetix:CVCL_0005, PubChem_Cell_line:CVCL_0005, Ubigen:YC-C122, Wikidata:Q54907527

ID: CVCL_0005

Record Creation Time: 20220427T220833+0000

Record Last Update: 20260829T234723+0000

Ratings and Alerts

No rating or validation information has been found for NB4.

No alerts have been found for NB4.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 53 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#).

van Eck van der Sluijs J, et al. (2026) Sialic acid cis-ligand dynamics modulate Siglec-7 and -9 function and affect Siglec-7/9 co-blockade to potentiate natural killer cell anti-tumor activity. *Oncoimmunology*, 15(1), 2649988.

Chen TQ, et al. (2026) RBM15B recognizes H3K79me2 to guide selective m6A-modification of mRNA and enhance oncoprotein translation in MLL-r leukemia. *The EMBO*

journal, 45(5), 1672.

Jones L, et al. (2026) A structure-based modeling approach identifies effective drug combinations for RAS-mutant acute myeloid leukemia. *iScience*, 29(8), 116875.

Uible EE, et al. (2026) Scaffolding-dependent CASP1 constrains excessive cell-intrinsic inflammatory signaling in leukemia. *Cell chemical biology*, 33(1), 59.

Pereira-Martins DA, et al. (2026) ??Np73 isoform defines a TP53-mutant-like poor-risk subgroup of acute myeloid leukemia. *Cell reports. Medicine*, 102540.

Su M, et al. (2026) FASN inactivation-induced progranulin (GRN) expression promotes lysosome-dependent cell death to suppress leukemogenesis. *Cell reports*, 45(3), 117042.

Leesang TE, et al. (2025) Retinoic acid and ascorbate synergize to suppress myeloid leukemia via TET2 activation. *Cell reports*, 44(10), 116379.

Giovannini S, et al. (2025) Thioredoxin-interacting protein (TXNIP) is a substrate of the NEDD4-like E3 ubiquitin-protein ligase WWP1 in cellular redox state regulation of acute myeloid leukemia cells. *Molecular oncology*, 19(1), 133.

Peled A, et al. (2025) BKT300: A Novel Anti-Leukemic Small Molecule Targeting the Protein Regulator of Cytokinesis 1 (PRC1) Pathway. *Research square*.

Shang K, et al. (2025) CD97-directed CAR-T cells with enhanced persistence eradicate acute myeloid leukemia in diverse xenograft models. *Cell reports. Medicine*, 6(6), 102148.

Chen Z, et al. (2025) YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies. *Cell*, 188(2), 331.

Balasundaram N, et al. (2025) A novel strategy to target metabolic dependencies in acute myeloid leukemia. *Cell death & disease*, 16(1), 792.

Venkataratnam Y, et al. (2025) Tunneling nanotubes between glioblastoma cells and T cells and hijack of mitochondria. *Journal of neuro-oncology*, 175(2), 571.

Biernacki MA, et al. (2025) SF3B1K700E Neoantigen Is a CD8+ T-cell Target Shared across Human Myeloid Neoplasms. *Cancer immunology research*, 13(9), 1391.

Chang YH, et al. (2024) SETDB1 suppresses NK cell-mediated immunosurveillance in acute myeloid leukemia with granulo-monocytic differentiation. *Cell reports*, 43(8), 114536.

Santana-Hern??ndez J, et al. (2024) Acute promyelocytic leukemia with PML/RARA (bcr1, bcr2 and bcr3) transcripts in a pediatric patient. *Oncology letters*, 27(3), 114.

Pallavi R, et al. (2024) Caloric restriction leads to druggable LSD1-dependent cancer stem cells expansion. *Nature communications*, 15(1), 828.

Guo HZ, et al. (2024) A CD36-dependent non-canonical lipid metabolism program promotes immune escape and resistance to hypomethylating agent therapy in AML. *Cell reports. Medicine*, 5(6), 101592.

Wang P, et al. (2024) Foretinib Is Effective in Acute Myeloid Leukemia by Inhibiting FLT3 and Overcoming Secondary Mutations That Drive Resistance to Quizartinib and Gilteritinib. *Cancer research*, 84(6), 905.

Han L, et al. (2023) METTL16 drives leukemogenesis and leukemia stem cell self-renewal by reprogramming BCAA metabolism. *Cell stem cell*, 30(1), 52.